May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
The Effect of Bevacizumab on Corneal Neovascularization in Rabbits
Author Affiliations & Notes
  • J. Lee
    Ophthalmology, St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
  • E. Jeon
    Ophthalmology, St. Paul's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
  • S. Chung
    Ophthalmology, St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
  • Footnotes
    Commercial Relationships  J. Lee, None; E. Jeon, None; S. Chung, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 1472. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J. Lee, E. Jeon, S. Chung; The Effect of Bevacizumab on Corneal Neovascularization in Rabbits. Invest. Ophthalmol. Vis. Sci. 2008;49(13):1472. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To determine the efficacy of topical application and subconjunctival injection of bevacizumab in the treatment of corneal neovascularization.

Methods: : Corneal neovascularization was induced with a silk suture of the corneal stroma in 8 rabbits(16 eyes). One week after suturing, 4 rabbits were treated with topical bevacizumab 5 mg/ml (A group) in the right eyes twice a day. Bevacizumab 1.25 mg/ml were injected subconjunctivally in the right eyes of 4 rabbits(B group). The all left eyes(8 eyes) were used as the control. The area of corneal neovascularization was measured and evaluated histologically using light microscopy. The concentration of vascular endothelial growth factor(VEGF) in corneal tissue was measured.

Results: : The neovascularized area was smaller in A and B groups than in control group (P <0.001). In analysis of the neovascularized area, there was no significant difference between group with treated topical bevacizumab 5 mg/ml (A group) and subconjunctival bevacizumab 1.25 mg injection(B group). The histologic examination revealed fewer new corneal vessels in treated group(A, and B groups) than control group. The corneal epithelium, stroma, and endothelium showed a normal appearance. The concentration of VEGF was 998.33±130.93 pg/ml in group A and 968.24±83.34 pg/ml in group B. The concentration of VEGF were significantly lower in the treated groups(A and B groups) than control group(1284.33±223.01 pg/ml)(P<0.01), but no difference was shown between treated groups(P>0.05).

Conclusions: : Topical and subconjunctival bevacizumab application may be useful in treatment of the corneal neovascularization and a further study will be necessary.

Keywords: cornea: basic science • neovascularization 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×